A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

Conditions

• Psoriatic Arthritis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Zasocitinib — DRUG
  Zasocitinib tablets.
• Placebo — DRUG
  Zasocitinib matching placebo.

Study Details

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.

Key Dates

Start date

Mar 10, 2025

Status verified

Apr 2026

Primary completion

May 18, 2027

Completion

Jan 26, 2028

Study Design

Enrollment

600 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Zasocitinib Dose A
  Participants will receive zasocitinib Dose A, tablets, orally, once daily (QD) for up to Week 52.
• Experimental: Zasocitinib Dose B
  Participants will receive zasocitinib Dose B, tablets, orally, QD for up to Week 52.
• Experimental: Placebo + Zasoctinib
  Participants will receive placebo, orally, QD for up to Week 16, followed by zasoctinib Dose A or Dose B, orally, QD, from Week 16 up to Week 52.

Primary Outcome Measure

Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 16 for Zasocitinib Dose A and B Compared to Placebo [ Time Frame: At Week 16 ]

Central Contacts

• Takeda Contact
  +1-877-825-3327
  [email protected]

Locations (21)

Find similar trials in Mesa, AZ

Related Studies

• Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
  Recruiting · University of California, San Diego · La Jolla, California
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  PHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
• Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
  Recruiting · M.D. Anderson Cancer Center · Houston, Texas
• Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
  PHASE3 · Recruiting · University of Pennsylvania · Loxahatchee Groves, Florida